INSM - Insmed sees brensocatib NDA for bronchiectasis in Q4
2024-07-03 15:05:54 ET
More on Insmed
- Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)
- Insmed announces pricing of $650M public offering
- Insmed intends to raise $500M via equity offering
- Insmed, Inc. (INSM) Q1 2024 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Insmed